NEUROCRINE BIOSCIENCES INCNBIXEarnings & Financial Report
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
NBIX Q2 FY2026 Key Financial Metrics
Revenue
$814.5M
Gross Profit
$800.7M
Operating Profit
$193.4M
Net Profit
$197.9M
Gross Margin
98.3%
Operating Margin
23.7%
Net Margin
24.3%
YoY Growth
42.2%
EPS
$1.91
NEUROCRINE BIOSCIENCES INC Q2 FY2026 Financial Summary
NEUROCRINE BIOSCIENCES INC reported revenue of $814.5M (up 42.2% YoY) for Q2 FY2026, with a net profit of $197.9M (24.3% margin). Cost of goods sold was $13.8M, operating expenses totaled $607.3M.
Key Financial Metrics
| Total Revenue | $814.5M |
|---|---|
| Net Profit | $197.9M |
| Gross Margin | 98.3% |
| Operating Margin | 23.7% |
| Report Period | Q2 FY2026 |
Revenue Breakdown
NEUROCRINE BIOSCIENCES INC Q2 FY2026 revenue of $814.5M breaks down across 3 segments, led by INGREZZA Net Product Sales at $656.9M (80.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| INGREZZA Net Product Sales | $656.9M | 80.7% |
| CRENESSITY Net Product Sales | $153.3M | 18.8% |
| Other Revenues | $4.3M | 0.5% |
NEUROCRINE BIOSCIENCES INC Revenue by Segment — Quarterly Trend
NEUROCRINE BIOSCIENCES INC revenue by segment across the last 4 reported quarters, showing how each business line (such as INGREZZA Net Product Sales and CRENESSITY Net Product Sales) has evolved quarter over quarter.
| Segment | Q2 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| INGREZZA Net Product Sales | $656.9M | $653.8M | $686.6M | $624.4M |
| CRENESSITY Net Product Sales | $153.3M | $135.4M | $98.1M | $53.2M |
| Other Revenues | $4.3M | — | — | — |
NEUROCRINE BIOSCIENCES INC Annual Revenue by Year
NEUROCRINE BIOSCIENCES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.9B).
NEUROCRINE BIOSCIENCES INC Quarterly Revenue & Net Profit History
NEUROCRINE BIOSCIENCES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $814.5M | +42.2% | $197.9M | 24.3% |
| Q4 FY2025 | $805.5M | +28.3% | $153.7M | 19.1% |
| Q3 FY2025 | $794.9M | +27.8% | $209.5M | 26.4% |
| Q2 FY2025 | $687.5M | +16.5% | $107.5M | 15.6% |
| Q1 FY2025 | $572.6M | +11.1% | $7.9M | 1.4% |
| Q4 FY2024 | $627.7M | +21.8% | $103.1M | 16.4% |
| Q3 FY2024 | $622.1M | +24.7% | $129.8M | 20.9% |
| Q2 FY2024 | $590.2M | +30.4% | $65.0M | 11.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $590.2M | $622.1M | $627.7M | $572.6M | $687.5M | $794.9M | $805.5M | $814.5M |
| YoY Growth | 30.4% | 24.7% | 21.8% | 11.1% | 16.5% | 27.8% | 28.3% | 42.2% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.31B | $3.54B | $3.72B | $3.69B | $3.89B | $4.27B | $4.63B | $4.91B |
| Liabilities | $795.8M | $816.1M | $1.13B | $1.15B | $1.20B | $1.26B | $1.38B | $1.50B |
| Equity | $2.51B | $2.72B | $2.59B | $2.54B | $2.69B | $3.00B | $3.25B | $3.41B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $64.6M | $158.0M | $242.5M | $64.8M | $102.0M | $227.5M | $388.4M |